Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+patients over 24 months - Results from the German TAFNES cohort study

被引：0
|
作者：
Stellbrink, H. [1 ]
Scholten, S.
Hillenbrand, H. [2 ]
Knechten, H. [3 ]
Jessen, H.
Schreiber, S. [4 ]
Goerner, K. [4 ]
Haubrich, R. [5 ]
Heinzkill, M. [4 ]
机构：
[1] ICH Study Ctr Hamburg, Clin Care, Hamburg, Germany
[2] MVZ Praxis City Ost, Clin Care, Berlin, Germany
[3] PZB, Clin Care, Aachen, Germany
[4] Gilead Sci, Med Affairs, Munich, Germany
[5] Gilead Sci, Med Affairs, Foster City, CA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P050
引用
收藏
页码：54 / 55
页数：2
相关论文
共 50 条
  • [41] Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
    Lathouwers, Erkki
    Wong, Eric Y.
    Brown, Kimberley
    Baugh, Bryan
    Ghys, Anne
    Jezorwski, John
    Mohsine, El Ghazi
    Van Landuyt, Erika
    Opsomer, Magda
    De Meyer, Sandra
    De Wit, S.
    Florence, E.
    Vandekerckhove, L.
    Vandercam, B.
    Brunetta, J.
    Klein, M.
    Murphy, D.
    Rachlis, A.
    Walmsley, S.
    Ajana, F.
    Cotte, L.
    Girard, P-M
    Katlama, C.
    Molina, J-M
    Poizot-Martin, I
    Raffi, F.
    Rey, D.
    Reynes, J.
    Teicher, E.
    Yazdanpanah, Y.
    Arasteh, K.
    Bickel, M.
    Bogner, J.
    Esser, S.
    Faetkenheuer, G.
    Jessen, H.
    Kern, W.
    Rockstroh, J.
    Spinner, C.
    Stellbrink, H-J
    Stoehr, A.
    Antinori, A.
    Castelli, F.
    Chirianni, A.
    De Luca, A.
    Di Biagio, A.
    Galli, M.
    Lazzarin, A.
    Maggiolo, F.
    Maserati, R.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2020, 36 (01) : 48 - 57
  • [42] A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results
    Perez-Valero, I.
    Llibre, J. M.
    Lazzarin, A.
    Di Perri, G.
    Pulido, F.
    Molina, J-M
    Esser, S.
    Margot, N.
    Shao, Y.
    Piontkowsky, D.
    Das, M.
    McNicholl, I.
    Haubrich, R.
    [J]. HIV MEDICINE, 2019, 20 : 170 - 171
  • [43] Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study
    Van Hemelryck, Sandyy
    Van Landuyt, Erika
    Hufkens, Veerle
    Vanveggel, Simon
    [J]. ANTIVIRAL THERAPY, 2024, 29 (02)
  • [44] An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)
    Camici, M.
    Mondi, A.
    Amendola, A.
    Abbate, I.
    Lorenzini, P.
    Ottou, S.
    Vergori, A.
    Plazzi, M. M.
    Bellagamba, R.
    Cicalini, S.
    Capobianchi, M. R.
    Antinori, A.
    Pinnetti, C.
    [J]. HIV MEDICINE, 2019, 20 : 86 - 86
  • [45] Doravirine/Islatravir (100mg/0.75mg) once daily compared to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as Initial HIV-1 treatment: 48 week results from a double-blind phase 3 trial
    Rockstroh, J. K.
    Paredes, R.
    Cahn, P.
    Molina, J. -M.
    Sokhela, S.
    Hinestrosa, F.
    Kassim, S.
    Ortega, E. Valencia
    Cunningham, D.
    Ghosn, J.
    Bogner, J. R.
    Gatanaga, H.
    Asante-Appiah, E.
    Zang, Y.
    Klopfer, S. O.
    Eves, K.
    Pisculli, M. L.
    Squires, K.
    Correll, T. A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [46] Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
    Eron, Joseph J.
    Orkin, Chloe
    Cunningham, Douglas
    Pulido, Federico
    Post, Frank A.
    De Wit, Stephane
    Lathouwers, Erkki
    Hufkens, Veerle
    Jezorwski, John
    Petrovic, Romana
    Brown, Kimberley
    Van Landuyt, Erika
    Opsomer, Magda
    De Wit, S.
    Florence, E.
    Moutschen, M.
    Van Wijngaerden, E.
    Vandekerckhove, L.
    Vandercam, B.
    Brunetta, J.
    Conway, B.
    Klein, M.
    Murphy, D.
    Rachlis, A.
    Shafran, S.
    Walmsley, S.
    Ajana, F.
    Cotte, L.
    Girardy, P. -M.
    Katlama, C.
    Molina, J. -M.
    Poizot-Martin, I.
    Raffi, F.
    Rey, D.
    Reynes, J.
    Teicher, E.
    Yazdanpanah, Y.
    Gasiorowski, J.
    Halota, W.
    Horban, A.
    Piekarska, A.
    Witor, A.
    Arribas, J. R.
    Perez-Valero, I.
    Berenguer, J.
    Casado, J.
    Gatell, J. M.
    Gutierrez, F.
    Galindo, M. J.
    Gutierrez, M. D. M.
    [J]. ANTIVIRAL RESEARCH, 2019, 170
  • [47] Week-48 results of AMBER: phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
    Gallant, J.
    Orkin, C.
    Molina, J-M
    Negredo, E.
    Antinori, A.
    Mills, A.
    Eron, J.
    Reynes, J.
    van Landuyt, E.
    Hufkens, V.
    Jezorwski, J.
    Opsomer, M.
    [J]. HIV MEDICINE, 2018, 19 : S32 - S32
  • [48] The effectiveness of E/C/F/TAF in treatment-naive (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey
    Inan, D.
    Ulu, A. Candevir
    Yildirim, F. Sarigul
    Ersoz, G.
    Komur, S.
    User, U.
    Kandemir, O.
    Kuscu, F.
    Cuvalci, N. Oztoprak
    Inal, A. S.
    Celen, M. K.
    Saba, R.
    Kurtaran, B.
    Tasova, Y.
    [J]. HIV MEDICINE, 2019, 20 : 82 - 83
  • [49] A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
    Valero, I. Perez
    Llibre, J. M.
    Lazzarin, A.
    Di Perri, G.
    Pulido, F.
    Molina, J. -M.
    Esser, S.
    McNicholl, I.
    Lorgeoux, R. -P.
    Margot, N.
    Shao, Y.
    Piontkowsky, D.
    Das, M.
    Haubrich, R.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 6 - 7
  • [50] Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naive and -experienced, virologically-suppressed adults living with HIV-1
    Huhn, Gregory D.
    Wilkin, Aimee
    Mussini, Cristina
    Spinner, Christoph D.
    Jezorwski, John
    El Ghazi, Mohsine
    Van Landuyt, Erika
    Lathouwers, Erkki
    Brown, Kimberley
    Baugh, Bryan
    [J]. HIV RESEARCH & CLINICAL PRACTICE, 2021, 21 (06) : 151 - 167
12345